Clinical trial
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
NCT00030043 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00030043 |
|---|---|
| Title | An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors |
| Official title | Penetrating Auditory Brainstem Implant for Neurofibromatosis 2 |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neurofibromatosis 2 |
| Intervention type | Device |
| Interventions | Penetrating auditory brainstem implant |
| Enrollment | 10 |
| Start date | Sep 1, 2001 |
| Completion | Aug 1, 2003 |
| First posted | Jan 31, 2002 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: